Showing results (1021-1030 of 1,192) with videos related to

Sort By:
Pageof 120
Cancer|April 13, 2018
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000Hagop M Kantarjian, Courtney D DiNardo, Graciela M Nogueras-Gonzalez, et al.
The Lancet. Haematology|January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trialRami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.
Blood|December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumabYasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2015
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic LeukemiaPiyanuch Kongtim, Uday Popat, Antonio Jimenez, et al.
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Leukemia|June 18, 2020
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortalityGhayas C Issa, Hagop M Kantarjian, Lianchun Xiao, et al.
Blood Advances|January 9, 2025
Advancing drug development in myelodysplastic syndromesAlain Mina, Kathy L McGraw, Lea Cunningham, et al.
Pageof 120